我們已在上線！進一步了解

First Tracks Biotherapeutics

TRAX

市值 US$12.3億

34.46 USD

-1.58

4.38%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

33.67

-0.79

2.29%

1天

-4.38%

5天

-12.65%

1個月

-11.64%

3個月

-4.83%

6個月

35.67%

今年迄今

81.37%

1年

81.37%

5年

81.37%

10年

81.37%

關於： First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 28.6%

中性 71.4%

負面 0%

First Tracks Biotherapeutics Announces $200 Million Private Placement

SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement at a price of $32.75 per share. First Tracks Biotherapeutics anticipates approximately $200 million in gross proceeds to the company before deducting placement agent fees and other expenses.

First Tracks Biotherapeutics Announces $200 Million Private Placement

First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor

First Tracks Biotherapeutics offers a differentiated CD122 antagonist, ANB033, showing promising Phase 1b data in celiac disease with statistically significant histology and symptom improvements. TRAX's ANB033 demonstrated a stronger efficacy signal versus Teva's IL-15 inhibitor, with a more pronounced reduction in mucosal injury and symptom severity under a harsher gluten challenge. With $168M in cash and a projected runway into Q2 2028, TRAX is positioned for late-stage celiac trials and expansion into two additional indications, but will likely require further financing.

First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor

First Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study Goals

First Tracks Biotherapeutics NASDAQ: TRAX reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met histologic and symptom-related objectives during a placebo-controlled gluten challenge.

First Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study Goals

First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday

U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Monday.

First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results

First Tracks Biotherapeutics Inc (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.

First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long

First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. I rate TRAX as a Hold due to post-spin instability, near-term dilution risk, and a multi-year path to revenue. ANB033 targets celiac disease, with no current FDA-approved therapies; pivotal trial data are expected in Q4 2026–2027, with commercialization likely a decade away.

First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long

查看新聞排名

價格圖表採用Lightweight Charts™實作